The copies will not be exactly identical to the originals
LONDON (Reuters) – The World Health Organization (WHO) is to launch a pilot project this year to assess cheap copies of expensive biotech cancer drugs in a bid to make such medicines more widely available in poorer countries.
The U.N. agency said on Thursday it would invite drugmakers in September to submit applications for prequalification of so-called biosimilar versions of two such drugs on its essential medicines list, Roche’s Rituxan and Herceptin.
WHO also plans to explore options for prequalifying biosimilar insulin.
Read Full Story Here >>